vs

Side-by-side financial comparison of AMDOCS LTD (DOX) and Dexcom (DXCM). Click either name above to swap in a different company.

Dexcom is the larger business by last-quarter revenue ($1.3B vs $1.3B, roughly 1.0× AMDOCS LTD). Dexcom runs the higher net margin — 21.2% vs 11.2%, a 10.0% gap on every dollar of revenue. On growth, Dexcom posted the faster year-over-year revenue change (21.6% vs 1.1%). Over the past eight quarters, Dexcom's revenue compounded faster (12.0% CAGR vs 4.5%).

Amdocs Limited is a multinational telecommunications technology company headquartered in Chesterfield, Missouri. The company specializes in software and services for communications, media and financial services providers and digital enterprises. Amdocs was founded in 1982 and is publicly traded on the Nasdaq stock exchange.

Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.

DOX vs DXCM — Head-to-Head

Bigger by revenue
DXCM
DXCM
1.0× larger
DXCM
$1.3B
$1.3B
DOX
Growing faster (revenue YoY)
DXCM
DXCM
+20.4% gap
DXCM
21.6%
1.1%
DOX
Higher net margin
DXCM
DXCM
10.0% more per $
DXCM
21.2%
11.2%
DOX
Faster 2-yr revenue CAGR
DXCM
DXCM
Annualised
DXCM
12.0%
4.5%
DOX

Income Statement — Q3 FY2024 vs Q1 FY2026

Metric
DOX
DOX
DXCM
DXCM
Revenue
$1.3B
$1.3B
Net Profit
$140.3M
$267.3M
Gross Margin
62.9%
Operating Margin
14.1%
25.6%
Net Margin
11.2%
21.2%
Revenue YoY
1.1%
21.6%
Net Profit YoY
-12.0%
153.6%
EPS (diluted)
$1.21
$0.67

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DOX
DOX
DXCM
DXCM
Q1 26
$1.3B
Q4 25
$1.3B
Q3 25
$1.2B
Q2 25
$1.2B
Q1 25
$1.0B
Q4 24
$1.1B
Q3 24
$994.2M
Q2 24
$1.3B
$1.0B
Net Profit
DOX
DOX
DXCM
DXCM
Q1 26
$267.3M
Q4 25
$267.3M
Q3 25
$283.8M
Q2 25
$179.8M
Q1 25
$105.4M
Q4 24
$151.7M
Q3 24
$134.6M
Q2 24
$140.3M
$143.5M
Gross Margin
DOX
DOX
DXCM
DXCM
Q1 26
62.9%
Q4 25
62.9%
Q3 25
60.5%
Q2 25
59.5%
Q1 25
56.9%
Q4 24
58.9%
Q3 24
59.7%
Q2 24
62.4%
Operating Margin
DOX
DOX
DXCM
DXCM
Q1 26
25.6%
Q4 25
25.6%
Q3 25
20.1%
Q2 25
18.4%
Q1 25
12.9%
Q4 24
17.0%
Q3 24
15.3%
Q2 24
14.1%
15.7%
Net Margin
DOX
DOX
DXCM
DXCM
Q1 26
21.2%
Q4 25
21.2%
Q3 25
23.5%
Q2 25
15.5%
Q1 25
10.2%
Q4 24
13.6%
Q3 24
13.5%
Q2 24
11.2%
14.3%
EPS (diluted)
DOX
DOX
DXCM
DXCM
Q1 26
$0.67
Q4 25
$0.67
Q3 25
$0.70
Q2 25
$0.45
Q1 25
$0.27
Q4 24
$0.37
Q3 24
$0.34
Q2 24
$1.21
$0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DOX
DOX
DXCM
DXCM
Cash + ST InvestmentsLiquidity on hand
$917.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.7B
Total Assets
$6.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DOX
DOX
DXCM
DXCM
Q1 26
$917.7M
Q4 25
$917.7M
Q3 25
$1.8B
Q2 25
$1.2B
Q1 25
$904.9M
Q4 24
$606.1M
Q3 24
$621.2M
Q2 24
$939.2M
Stockholders' Equity
DOX
DOX
DXCM
DXCM
Q1 26
$2.7B
Q4 25
$2.7B
Q3 25
$2.7B
Q2 25
$2.6B
Q1 25
$2.3B
Q4 24
$2.1B
Q3 24
$2.0B
Q2 24
$2.4B
Total Assets
DOX
DOX
DXCM
DXCM
Q1 26
$6.3B
Q4 25
$6.3B
Q3 25
$7.5B
Q2 25
$7.3B
Q1 25
$6.8B
Q4 24
$6.5B
Q3 24
$6.4B
Q2 24
$6.8B

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons